📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. (2021)

First Author: Cresswell FV

Attributed to: Immunomodulation and Vaccines funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1093/cid/ciab162

PubMed Identifier: 33693537

Publication URI: http://europepmc.org/abstract/MED/33693537

Type: Journal Article/Review

Volume: 73

Parent Publication: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Issue: 5

ISSN: 1058-4838